BioStock: AdjuTec advances toward phase I with regulatory green light
Preparing to hit the clinical stage with its antibiotic resistance breakers, Norwegian AdjuTec Pharma recently got a goahead from the Swedish Medical Products Agency. The company now hopes to begin single ascending dose studies after the summer break. – The team has done a great job in preparing the clinical trial application. We have had a good dialogue with the Swedish authorities and the process has been really smooth, CEO Bjørn Klem tells BioStock.Läs hela artikeln på biostock.se : https://www.biostock.se/en/2024/05/adjutec-advances-toward-phase-i-with-